This podcast surveys state-of-the-art presentations on clinical oncology findings on mCRPC, metastatic oesophageal squamous cell cancer, primary breast cancer, and more.
In a digital format amid the COVID-19 pandemic, the global oncology community met this year to continue fostering knowledge-sharing.
This ASCO 2021 correspondent's podcast revisits six congress state-of-the-art presentations on clinical oncology themes that included new findings on the global scientific race to battle mCRPC, metastatic oesophageal squamous cell cancer, primary breast cancer, locoregional clear cell renal cell cancer, and melanoma.
Today's podcast discusses six presentations that took place during this year's American Society of Clinical Oncology (ASCO) 2021 annual meeting, which took place digitally this year 4-8 August. The presentations covered in this podcast include:
A first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant treatment with the PARP inhibitor olaparib.
First results of the phase 3 KEYNOTE-564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC).
First results of the phase 3 RELATIVITY-047 trial validate the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma.
In the phase 2 NANT2011-01 trial, levels of circulating tumour DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time.
You can also visit esanum's dedicated page to the ASCO 2021 digital annual meeting here.